Actinogen Medical (ACW.AX) traded down -2.13 % during a 24 hours period ending at 04:05 PM Central Europe on Monday 26th. One Actinogen Medical stock can currently be bought for about AUD 0.04 on popular exchanges. Current supply of Actinogen Medical stocks is 3.8 bn. Actinogen Medical has a current market capitalization of AUD 177 mn and approximately AUD 229.6 k worth of Actinogen Medical was traded on exchanges in the last 24 hours. Since last month end, Actinogen Medical has traded -22.03 % down. Simple moving average of last 200 days is at AUD 0.04. The highest price of past 52 weeks was recorded at AUD 0.07 on 01/07/2026. 52 weeks low was at AUD 0.03 on 06/30/2026.
Here is how related stocks have performed in the past 24 hours:
American Rare Earths (ARR.AX) traded flat 0 % and now trades at AUD 0.32. American Rare Earths has a market capitalisation of AUD 209.7 mn. American Rare Earths Ltd is preparing to hold its 2026 Annual General Meeting, where shareholders will consider a range of corporate and remuneration matters. The agenda includes the adoption of the Remuneration Report, the re‑election of a director and the approval of proposed equity awards. Directors will receive shares to satisfy a portion of their fees, and the company will seek approval for performance‑right awards for the chief executive and non‑executive directors. Shareholder consent is also requested to enable the company to issue additional equity under a 10 % placement facility, which would expand its capital‑raising options. The resolutions are framed to align remuneration with shareholder interests while maintaining compliance with listing and corporate governance requirements.
Horizon Gold (HRN.AX) traded down -1.4 % and now trades at AUD 1.1. Current market capitalisation for Horizon Gold is AUD 205.9 mn. Horizon Gold Limited announced that its upcoming annual general meeting will convene on 25 November 2026. Shareholders will review the company’s financial statements for the year ended 30 June 2026, including the directors’ report and remuneration details, and consider the adoption of the remuneration report. The meeting will also address several board‑related resolutions: the re‑election of Director Scott Williamson, the election of new directors Warrick Clent and Rob Curtis, and the approval of a 7.1A mandate that would allow the company to issue additional equity securities without further shareholder consent. Moreover, shareholders will vote on the issuance of zero‑exercise‑price options to directors as part of a performance‑linked incentive plan. The agenda reflects standard corporate governance matters and a planned expansion of the company’s share‑capital framework.
Humm (HUM.AX) traded down -1.19 % and now trades at AUD 0.42. Current market capitalisation for Humm is AUD 212.2 mn. Humm has a current price to earnings ratio of 13.39.
Carnaby (CNB.AX) traded down -5.06 % and now trades at AUD 0.77. Carnaby has a market capitalisation of AUD 207.1 mn.
Maritana Minerals (MRT.AX) traded down -6.9 % and now trades at AUD 0.57. Maritana Minerals has a market capitalisation of AUD 201.5 mn. Current price/earnings ratio for Maritana Minerals is 2.12. Maritana Minerals Ltd reported its latest quarterly cash flow statement for the period ending 30 September 2026. The company’s operating activities showed a modest outflow, largely driven by exploration and evaluation expenses, while cash inflows included interest receipts. Investment outflows were significant, reflecting purchases of tenements, property, plant and equipment, and refurbishment of the Black Swan Processing Plant. Financing activity remained largely unchanged, with a small net cash use attributable to lease liability repayment and option exercise. Overall, the company experienced a net decrease in cash and cash equivalents during the quarter, reducing its balance to just over $214,000. The statement highlights the company’s ongoing focus on exploration and development activities, with cash outflows concentrated on advancing its mining assets and infrastructure.
About Actinogen Medical
Actinogen Medical Limited is a biotechnology company based in Sydney, Australia, that specializes in developing treatments for Alzheimer’s disease and mild cognitive impairment. The company has its sights set on creating a novel drug to address these age-related neurodegenerative conditions and other related diseases. You can find more information about their operations and offerings on their website, www.actinogen.com.au , and they are listed on the ASX All Markets stock exchange. Their Initial Public Offering (IPO) took place on October 15, 2007.
